Status:
COMPLETED
Tofacitinib Ointment For Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis Vulgaris
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice da...
Eligibility Criteria
Inclusion
- Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline
- At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)
- If received certain treatments, should be off treatment for a minimum period of time (washout)
Exclusion
- Currently have non-plaque forms of psoriasis or drug-induced psoriasis
- Require treatment with or cannot stop medication(s) prohibited during the study
- Have certain laboratory abnormalities at Baseline
- Current or history of certain infections
- Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
476 Patients enrolled
Trial Details
Trial ID
NCT01831466
Start Date
May 1 2013
End Date
September 1 2014
Last Update
November 25 2015
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
2
Bakersfield Dermatology and Skin Cancer Medical Center
Bakersfield, California, United States, 93304
3
UC Irvine Dermatology Research
Irvine, California, United States, 92697
4
Dermatology Research Associates
Los Angeles, California, United States, 90045